Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georgia Metzgeroth

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
American Journal of Hematology|May 29, 2015
KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significanceJuliana Schwaab, Roland Umbach, Georgia Metzgeroth, et al.
Annals of Hematology|April 3, 2023
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysisJohannes Lübke, Nicole Naumann, Georgia Metzgeroth, et al.
Blood|April 21, 2017
Response and progression on midostaurin in advanced systemic mastocytosis: <i>KIT</i> D816V and other molecular markersMohamad Jawhar, Juliana Schwaab, Nicole Naumann, et al.
Leukemia|March 27, 2019
Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosisJohannes Lübke, Nicole Naumann, Sebastian Kluger, et al.
Genes, Chromosomes & Cancer|July 18, 2006
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion geneChristoph Walz, Claire Curtis, Susanne Schnittger, et al.
Blood|June 28, 2011
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3Christoph Walz, Philipp Erben, Michael Ritter, et al.
Blood|December 15, 2005
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alphaAmy V Jones, Richard T Silver, Katherine Waghorn, et al.
Haematologica|March 4, 2017
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasmMohamad Jawhar, Juliana Schwaab, Manja Meggendorfer, et al.
Haematologica|January 29, 2010
Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysisPhilipp Erben, Darko Gosenca, Martin C Müller, et al.
Cancers|February 10, 2024
Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in <i>KIT</i> D816V-Negative Advanced Systemic MastocytosisNicole Naumann, Martina Rudelius, Johannes Lübke, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
American Journal of Hematology|May 29, 2015
KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significanceJuliana Schwaab, Roland Umbach, Georgia Metzgeroth, et al.
Annals of Hematology|April 3, 2023
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysisJohannes Lübke, Nicole Naumann, Georgia Metzgeroth, et al.
Blood|April 21, 2017
Response and progression on midostaurin in advanced systemic mastocytosis: <i>KIT</i> D816V and other molecular markersMohamad Jawhar, Juliana Schwaab, Nicole Naumann, et al.
Leukemia|March 27, 2019
Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosisJohannes Lübke, Nicole Naumann, Sebastian Kluger, et al.
Genes, Chromosomes & Cancer|July 18, 2006
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion geneChristoph Walz, Claire Curtis, Susanne Schnittger, et al.
Blood|June 28, 2011
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3Christoph Walz, Philipp Erben, Michael Ritter, et al.
Blood|December 15, 2005
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alphaAmy V Jones, Richard T Silver, Katherine Waghorn, et al.
Haematologica|March 4, 2017
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasmMohamad Jawhar, Juliana Schwaab, Manja Meggendorfer, et al.
Haematologica|January 29, 2010
Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysisPhilipp Erben, Darko Gosenca, Martin C Müller, et al.
Cancers|February 10, 2024
Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in <i>KIT</i> D816V-Negative Advanced Systemic MastocytosisNicole Naumann, Martina Rudelius, Johannes Lübke, et al.
Pageof 9